SCHEMBL934473

SCHEMBL934473

O=C(Cl)C(Sc1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.61
SMN1; SMN2 Q16637 3/20 0.56
PKM P14618 1/20 0.56
MAPT P10636 4/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 1/20 0.51
KDM4E B2RXH2 1/20 0.51
PAX8 Q06710 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
NPSR1 Q6W5P4 3/20 0.49
POLB P06746 2/20 0.49
EPHX1 P07099 1/20 0.49
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933431 0.89 CYP2C9 (0.53) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL934969 0.88 LMNA (0.49) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL5420619 0.88 LMNA (0.53) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL934324 0.85 EPHX1 (0.51) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL645517 0.83 LMNA (0.65) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL933324 0.81 EPHX1 (0.44) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL6796251 0.80 EPHX1 (0.71) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL4262200 0.80 LMNA (0.66) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL933787 0.78 HSD17B10 (0.53) LMNASMN1; SMN2MAPTL3MBTL1MEN1
SCHEMBL10882291 0.78 LMNA (0.59) LMNASMN1; SMN2PKMMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 LMNA 2211/4885SMN1; SMN2 3896/4885PKM 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.